NCBI Taxonomy: 66872
Streptomyces baarnensis (ncbi_taxid: 66872)
found 8 associated metabolites at species taxonomy rank level.
Ancestor: Streptomyces fimicarius subgroup
Child Taxonomies: none taxonomy data.
Enaminomycin C
Enaminomycin C is a metabolite that has been isolated from Streptomyces species, which are a group of bacteria known for their ability to produce a wide array of secondary metabolites with diverse biological activities. Enaminomycin C is one such compound that has been identified and characterized from these bacteria. It belongs to the enediyne antibiotic class, which are complex natural products known for their potent antibacterial activity, particularly against Gram-positive bacteria. Enaminomycin C, like other enediyne antibiotics, is believed to exert its antibacterial effects by targeting the bacterial ribosome and forming a complex with the RNA, leading to the inhibition of protein synthesis and ultimately cell death. The structural features of Enaminomycin C contribute to its unique biological properties. It possesses an enediyne core, which is a key structural element responsible for its antibacterial activity. Additionally, it may have other functional groups or substituents that can influence its pharmacological properties, such as absorption, distribution, metabolism, and excretion. As a natural product with potential antimicrobial activity, Enaminomycin C and other related compounds have been of interest in the field of drug discovery and development. Researchers are interested in understanding their mechanisms of action, as well as exploring the potential for modifying these compounds to improve their therapeutic profiles, such as increasing potency, reducing toxicity, or expanding the spectrum of activity against drug-resistant bacteria. However, it is important to note that while Enaminomycin C has been identified and characterized from Streptomyces species, it may not have been extensively studied or developed into a therapeutic agent. Further research is needed to fully understand its potential as a novel antimicrobial agent and to address any challenges associated with its development, such as synthesis, scalability, and clinical trials.
